ZappRx’s new digital platform for prescribing specialty medications, including therapies to treat pulmonary fibrosis, can now be used at two centers with expertise in respiratory conditions — Arizona Pulmonary Specialists and Harbor-UCLA Medical Center.
The platform was designed to speed up and simplify the complex process required to order specialty medications by reducing the administrative burden. It allows healthcare providers, pharmacists, and payers to virtually interact with each another when filling a prescription, cutting the time spent on prescribing and managing specialty drugs.
Patients can also follow the status of their prescriptions, and pharmaceutical companies can easily assess the process performance with real-time clinical data. The platform is currently established in three disease areas: idiopathic pulmonary fibrosis, pulmonary arterial hypertension, and cystic fibrosis. ZappRx plans to expand the platform to support other medical areas, including neurology, oncology, rheumatology, and gastroenterology conditions.
“The first prescription we wrote was approved within 48 hours, improving immediately on what had been a completely paper-based process for us, taking sometimes more than three weeks,” Ronald Oudiz, MD, director of the Liu Center for Pulmonary Hypertension, LA Biomedical Research Institute at Harbor-UCLA who led the implementation of the platform there, said in a news release.
“Our team spends its time differently now that we use ZappRx,” added Jeremy Feldman, MD, director of the Pulmonary Hypertension Program in Arizona. “The nurses worry less about the prescriptions and prior authorizations for our patients, and are able to spend more time with patients, and less time on the phone with insurance companies. The nurses also connect with the doctors more on patient care, and are generally less stressed about their jobs.”
Feldman was involved in the implementation of the ZappRx platform at Arizona Pulmonary Specialists.
“Dr. Feldman raised his hand to be first to use our combined prescription and prior authorization feature set. We love that innovators on the clinical front like Drs. Feldman and Oudiz are showing leadership in technology innovation too, and that ZappRx is the vehicle for it,” said Karen Tirozzi, ZappRx’s vice president of solutions.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?